Advantages of Abzyme’s antibody discovery platform include:

Triple-mode system: Simultaneously uses an in vivo antibody maturation, a switchable antibody surface display and an antibody secretion mode to accelerate the antibody selection, optimization and production processes.

In vivo antigen-directed antibody affinity maturation: Mimicking mammalian antibody diversification and affinity maturation processes

Eukaryotic-based in vitro selection system: Filters for well-expressing and manufacturable antibody candidates

Antibody generation against difficult targets: The animal-free system enables us to develop antibodies to a variety of difficult targets including, non-immunogenic and highly toxic antigens as well as cell surface antigens for membrane protein antibody production.

Unsurpassed diversity: Unprecedented diversity of human antibodies thanks to random pairing of heavy and light chains in combination with inducible somatic hypermutation.

Speed of development: Each discovery/optimization cycle finishes within weeks from target to antibodies with desired attributes.

FACS-based approach identifies desired antibodies: Advanced process for identifying antibodies with desired attributes

Advanced antibody optimization capabilities: Rapidly optimize leads into best-in-class therapeutic candidates

Consistency across production batches: Recombinant monoclonal antibody with known amino acid sequences

Abzyme’s antibody discovery platform incorporates the ability to select for key properties such as epitopic diversity, binding affinity, expressibility, solubility, developability, broad-reactivity and target-specificity into real-time screening.

In addition, Abzyme’s single domain antibody platform in combination with a modular plug-and-play approach enables generation of novel bispecific (Abz2) antibodies for novel therapies and rapid reformatting existing antibodies into bispecific antibodies to improve therapeutic indices.